Gene test may predict chemo toxicity in breast cancer patients
NCT ID NCT00953537
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tested whether a gene deficiency (DPD) can predict severe side effects from the chemotherapy drug capecitabine in women with metastatic breast cancer. Researchers analyzed blood samples from 303 participants to look for links between genetics and toxicities like diarrhea and hand-foot syndrome. The goal is to help doctors personalize treatment and reduce harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.